Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $14.46 Analyst target: $44.50 Upside: 207.82%
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
See the full interactive analysis & chart →Informational only — not investment advice.